Biovest nets acceptance for BiovaxID
Worcester-based Biovest International announced it has received notification from the Commission of the European Union that its BiovaxID therapy for Follicular Lymphoma has gained entry on the European Community's Drug Register for Rare Diseases.
Biovest, a firm specializing in the development of advanced immunotherapies for life-threatening cancers of the blood system, is seeking final approval to market BiovaxID in the European Union. The latest designation offers benefits to BioVest in its development and marketing of the therapy in the EU, which names treatments to the Drug Register for Rare Diseases to target those disorders that affect fewer than 5 in 10,000 people.
The designation will also allow Biovest to take advantage of direct assistance from the European Medicines Agency in preparing the final protocol for drug approval, among other benefits.
WBJ Web Partners
Most Recent
0 Comments